Sana Biotechnology, Inc.
NASDAQ:SANA · NASDAQ Global Select
+$0.04 today
Vol 4.71M · Avg 3.76M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SANA · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$242.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.92, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $12.8M | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$12.8M | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $132.0M -36.8% | $208.7M -5.1% | $219.8M +9.4% | $201.0M -34.4% | $306.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $44.3M -30.8% | $64.0M -12.6% | $73.3M +2.4% | $71.6M +42.0% | $50.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $178.2M -34.7% | $272.7M -7.0% | $293.1M +7.5% | $272.6M -23.6% | $356.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $12.8M -26.7% | $17.4M -29.2% | $24.6M +57.2% | $15.6M +41.1% | $11.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$231.4M +7.2% | -$249.4M +3.6% | -$258.7M -1.9% | -$253.9M +26.4% | -$344.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$191.0M +30.0% | -$272.7M +7.0% | -$293.1M -7.5% | -$272.6M +23.6% | -$356.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.8M -63.3% | $10.5M +5.4% | $9.9M +164.2% | $3.8M +456.5% | $676.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$53.2M -992.2% | $6.0M -39.7% | $9.9M +220.1% | $3.1M +214.8% | $981.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$244.2M +8.5% | -$266.8M +5.8% | -$283.3M -5.1% | -$269.5M +24.3% | -$355.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$244.2M +8.5% | -$266.8M +5.8% | -$283.3M -5.1% | -$269.5M +24.3% | -$355.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +17.2% | -$1 +20.5% | -$1 -2.1% | -$1 +33.2% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +17.2% | -$1 +20.5% | -$1 -2.1% | -$1 +33.2% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $253.2M +9.7% | $230.9M +18.7% | $194.5M +3.3% | $188.3M +13.2% | $166.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $253.2M +9.7% | $230.9M +18.7% | $194.5M +3.3% | $188.3M +13.2% | $166.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.38B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.81B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.87B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.70B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.48B
Inhibrx Biosciences, Inc.
NASDAQ:INBX
$1.35B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Xencor, Inc.
NASDAQ:XNCR
$937.75M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$855.60M
Oculis Holding AG
NASDAQ:OCS
$628.29M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SANA generate?
Sana Biotechnology, Inc. (SANA) reported $0.00 of revenue in fiscal 2025.
Is SANA profitable?
Sana Biotechnology, Inc. (SANA) reported -$244,166,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.